|
1
|
Wright EM, Loo DD and Hirayama BA: Biology
of human sodium glucose transporters. Physiol Rev. 91:733–794.
2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nauck MA: Update on developments with
SGLT2 inhibitors in the management of type 2 diabetes. Drug Des
Devel Ther. 8:1335–1380. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Täger T, Atar D, Agewall S, Katus HA,
Grundtvig M, Cleland JGF, Clark AL, Fröhlich H and Frankenstein L:
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors
(SGLT2i) for cardiovascular outcomes in type 2 diabetes: A
systematic review and network meta-analysis of randomised
controlled trials. Heart Fail Rev. 26:1421–1435. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fernandes GC, Fernandes A, Cardoso R,
Penalver J, Knijnik L, Mitrani RD, Myerburg RJ and Goldberger JJ:
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac
death in patients with type 2 diabetes or heart failure: A
meta-analysis of 34 randomized controlled trials. Heart Rhythm.
18:1098–1105. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zelniker TA, Wiviott SD, Raz I, Im K,
Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM,
et al: SGLT2 inhibitors for primary and secondary prevention of
cardiovascular and renal outcomes in type 2 diabetes: A systematic
review and meta-analysis of cardiovascular outcome trials. Lancet.
393:31–39. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ujjawal A, Schreiber B and Verma A:
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney
transplant recipients: What is the evidence? Ther Adv Endocrinol
Metab. 13(20420188221090001)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen S, Coronel R, Hollmann MW, Weber NC
and Zuurbier CJ: Direct cardiac effects of SGLT2 inhibitors.
Cardiovasc Diabetol. 21(45)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Packer M, Anker SD, Butler J, Filippatos
G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann
M, et al: Cardiovascular and renal outcomes with empagliflozin in
heart failure. N Engl J Med. 383:1413–1424. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
De Marzo V, Savarese G, Porto I, Metra M
and Ameri P: Efficacy of SGLT2-inhibitors across different
definitions of heart failure with preserved ejection fraction. J
Cardiovasc Med (Hagerstown). 24:537–543. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Younes AM, Salem M, Maraey A, Nomigolzar
S, Sewell K, Khalil M, Elzanaty A, Saeyeldin A and Dar M: Safety
outcomes of SGLT2i in the heart failure trials: A systematic review
and meta-analysis. Int J Cardiol. 366:51–56. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li X, Wu H, Peng H and Jiang H: Comparison
the effects of finerenone and SGLT2i on cardiovascular and renal
outcomes in patients with type 2 diabetes mellitus: A network
meta-analysis. Front Endocrinol (Lausanne).
13(1078686)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wiviott SD, Raz I, Bonaca MP, Mosenzon O,
Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et
al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 380:347–357. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zinman B, Wanner C, Lachin JM, Fitchett D,
Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ,
et al: Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 373:2117–2128. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: Prisma group. Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med. 151:264–269.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tromp J, Ouwerkerk W, van Veldhuisen DJ,
Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CS and Voors
AAJHF: A systematic review and network meta-analysis of
pharmacological treatment of heart failure with reduced ejection
fraction. JACC Heart Fail. 10:73–84. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shentu Y, Li Y, Xie S, Jiang H, Sun S, Lin
R, Chen C, Bai Y, Zhang Y, Zheng C and Zhou Y: Empagliflozin, a
sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal
fibrosis via suppressing TGF-β/Smad signaling. Int Immunopharmacol.
93(107374)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dharmalingam M, Aravind SR, Thacker H,
Paramesh S, Mohan B, Chawla M, Asirvatham A, Goyal R, Shembalkar J,
Balamurugan R, et al: Efficacy and safety of remogliflozin
etabonate, a new sodium glucose co-transporter-2 inhibitor, in
patients with type 2 diabetes mellitus: A 24-week, randomized,
double-blind, active-controlled trial. Drugs. 80:587–600.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cao Y, Li P, Li Y and Han Y:
Sodium-glucose cotransporter-2 inhibitors in heart failure: An
updated meta-analysis. ESC Heart Fail. 9:1942–1953. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kaze AD, Zhuo M, Kim SC, Patorno E and
Paik JM: Association of SGLT2 inhibitors with cardiovascular,
kidney, and safety outcomes among patients with diabetic kidney
disease: A meta-analysis. Cardiovasc Diabetol.
21(47)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Koyani CN, Plastira I, Sourij H, Hallström
S, Schmidt A, Rainer PP, Bugger H, Frank S, Malle E and von
Lewinski D: Empagliflozin protects heart from inflammation and
energy depletion via AMPK activation. Pharmacol Res.
158(104870)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Usman MS, Siddiqi TJ, Memon MM, Khan MS,
Rawasia WF, Ayub MT, Sreenivasan J and Golzar Y: Sodium-glucose
co-transporter 2 inhibitors and cardiovascular outcomes: A
systematic review and meta-analysis. Eur J Prev Cardiol.
25:495–502. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zelniker TA, Wiviott SD, Raz I, Im K,
Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A,
et al: Comparison of the effects of glucagon-like peptide receptor
agonists and sodium-glucose cotransporter 2 inhibitors for
prevention of major adverse cardiovascular and renal outcomes in
type 2 diabetes mellitus. Circulation. 139:2022–2031.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
American Diabetes Association. 2.
Classification and diagnosis of diabetes: standards of medical care
in diabetes-2019. Diabetes Care. 42:S13–S28. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chatterton H, Younger T, Fischer A and
Khunti K: Programme Development Group. Risk identification and
interventions to prevent type 2 diabetes in adults at high risk:
Summary of NICE guidance. BMJ. 345(e4624)2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Salah HM and Fudim M: Sodium-glucose
cotransporter 2 inhibitors and nonalcoholic fatty liver disease.
Heart Fail Clin. 18:625–634. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Spertus JA, Birmingham MC, Nassif M,
Damaraju C, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN
and Januzzi JL: The SGLT2 inhibitor canagliflozin in heart failure:
The CHIEF-HF remote, patient-centered randomized trial. Nat Med.
28:809–813. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Martinez FA, Serenelli M, Nicolau JC,
Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE,
Køber L, Kosiborod MN, et al: Efficacy and safety of dapagliflozin
in heart failure with reduced ejection fraction according to age:
Insights from DAPA-HF. Circulation. 141:100–111. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pan D, Xu L, Chen P, Jiang H, Shi D and
Guo M: Empagliflozin in patients with heart failure: A systematic
review and meta-analysis of randomized controlled trials. Front
Cardiovasc Med. 8(683281)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chambergo-Michilot D, Tauma-Arrué A and
Loli-Guevara SJIH: Effects and safety of SGLT2 inhibitors compared
to placebo in patients with heart failure: A systematic review and
meta-analysis. Int J Cardiol Heart Vasc. 32(100690)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yan Y, Liu B, Du J, Wang J, Jing X, Liu Y,
Deng S, Du J and She Q: SGLT2i versus ARNI in heart failure with
reduced ejection fraction: A systematic review and meta-analysis.
ESC Heart Fail. 8:2210–2219. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gager GM, von Lewinski D, Sourij H, Jilma
B, Eyileten C, Filipiak K, Huelsmann M, Kubica J, Postula M and
Siller-Matula JM: Effects of SGLT2 inhibitors on ion homeostasis
and oxidative stress associated mechanisms in heart failure. Biomed
Pharmacother. 143(112169)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kato ET, Silverman MG, Mosenzon O,
Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL,
Leiter LA, et al: Effect of Dapagliflozin on heart failure and
mortality in type 2 diabetes mellitus. Circulation. 139:2528–2536.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Petrie MC, Verma S, Docherty KF, Inzucchi
SE, Anand I, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer
RA, et al: Effect of dapagliflozin on worsening heart failure and
cardiovascular death in patients with heart failure with and
without diabetes. JAMA. 323:1353–1368. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Anker SD, Butler J, Filippatos G, Khan MS,
Marx N, Lam CS, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, et
al: Effect of empagliflozin on cardiovascular and renal outcomes in
patients with heart failure by baseline diabetes status: Results
from the EMPEROR-reduced trial. Circulation. 143:337–349.
2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
McMurray JJ, Solomon SD, Inzucchi SE,
Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS,
Anand IS, Bělohlávek J, et al: Dapagliflozin in patients with heart
failure and reduced ejection fraction. N Engl J Med. 381:1995–2008.
2019.PubMed/NCBI View Article : Google Scholar
|
